BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Vaccines

  UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight

  A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.

  November 20, 2024

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Podcast

  RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

  Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

  November 20, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  MASH

  Novo, Viking Heat Up MASH Space with Promising Data at AASLD24

  Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging backbone of MASH treatment, with the potential to combine it with other drug classes to achieve deeper responses, according to BMO Capital Markets analyst Evan Seigerman.

  November 20, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Huntington’s disease

  Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data

  After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.

  November 20, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  The End of Chevron Deference Could Open a New Era of Biotech

  While the full impact of the Supreme Court decision remains unknown, the new regulatory landscape could be a net positive for drug developers.

  November 20, 2024

   · 

  6 min read

   · 

  Anshul Mangal
• 

  Rare diseases

  Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D

  A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

  November 20, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Government

  Trump to Appoint Celebrity Physician Dr. Oz to Head CMS

  The selection of controversial TV personality Mehmet Oz to run the agency overseeing Medicare and Medicaid follows Trump’s pick of RFK Jr. to run its parent department, HHS.

  November 20, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Executive Appointments

  Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO

  Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.

  November 20, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

  November 20, 2024

   · 

  2 min read
• Press Releases

  DELFI Diagnostics Selects Lahey Hospital & Medical Center to Administer New Lung Cancer Screening Test

  November 20, 2024

   · 

  2 min read